@FiercePharma: Top-read story over the long weekend: Gilead's Sovaldi, GSK's Anoro stand out in 2014's blockbuster crop, report says. Story | Follow @FiercePharma
@TracyStaton: Juicy trade-secrets dispute between Bristol-Myers + its ad agency and an account manager who jumped ship. More from MediaPost | Follow @TracyStaton
@EricPFierce: Bill that would have paid drug disposal costs in California out of pharma's pocket left in the recycle bin. Article | Follow @EricPFierce
@CarlyHFierce: Full steam ahead for Copaxone copies as SCOTUS denies Teva's bid for delay. More | Follow @CarlyHFierce
> Actavis ($ACT) said its president of global R&D, G. Frederick Wilkinson, will leave the company to take the helm of generics rival Impax Laboratories ($IPXL). Release
> GlaxoSmithKline's ($GSK) chronic obstructive pulmonary disease treatment Incruse Ellipta won approval in Canada. Release
> A Chicago jury awarded $14 million to a woman who sued her doctor over a stroke she suffered after taking Bayer's birth control pill Yasmin. Report
> Merck Serono's new president and CEO, Belén Garijo, has been appointed as an independent director of L'Oréal. Report
> Drug side-effects data company AdverseEvents closed a $2 million Series A funding round, aiming to expand its sales force and analyst teams, and step up marketing efforts. Release
> Cubist Pharma pulled one lot of its antibiotic Cubicin after a customer reported glass particles in a vial from that lot. Report
@FierceMedDev: OPKO Health to buy Israeli inhaler developer Inspiro Medical for undisclosed price. News | Follow @FierceMedDev
@VarunSaxena2: Report: Pfizer pitches $101B megamerger to struggling AstraZeneca - FierceBiotech. More from FierceBiotech | Follow @VarunSaxena2
@EmilyWFierce: Wearable data glove that translates motion into sound could mean big things for the American deaf community. Story | Follow @EmilyWFierce
@MichaelGFierce: MIT team delivers three ovarian cancer drugs with one particle. Article from FierceDrugDelivery | Follow @MichaelGFierce
> Medtronic, Edwards need heart-to-heart over post-injunction access. More
> EndoStim bags a CE mark for MRI-safe reflux device. Item
> Advanced Cardiac Therapeutics raises $7M-plus for ablation catheter technology. Story
Biotech News
@FierceBiotech: Former Creighton professor named chief medical officer at 23andMe. Roundup | Follow @FierceBiotech
@JohnCFierce: I added the top 5 rounds from Q1 in my biotech VC story. And not a one of the biotechs is in the Boston area. Story | Follow @JohnCFierce
@DamianFierce: Here's some NYTimes background on the procedure FDA's warning about (with a remarkably NYTish headline): Article (sub. req.)| Follow @DamianFierce
@EmilyMFierce: New MRSA superbug emerges in Brazilian patient. Story | Follow @EmilyMFierce
> Sarepta rockets up after mapping a shortcut to the FDA with DMD hopeful eteplirsen. Story
> Zafgen tees up an $86M IPO for eye-catching obesity drug. More
> Say what? Pfizer's $101B buyout pitch to AstraZeneca sparks a megadebate. News
CRO News
> Certara buys Synchrogenix with its eye on regulatory writing. Story
> InVentiv signs up to get IntelliCell's regenerative drug into the clinic. More
> AMRI plans to shutter an R&D shop to save cash. Article
> Quintiles taps OmniComm for early-stage data management. News
> WuXi poaches an AstraZeneca exec to amp up Chinese R&D. Report
Biotech IT News
> U.K. and Canadian governments back bioinformatics, omics research projects. More
> BlackBerry plans healthcare-focused smartphone after making eClinical investment. Story
> Europe puts data management at the heart of $4B drug innovation drive. Article
> Pfizer, PhRMA and others pick holes in FDA social media guidance. News
> Google adds UCSF geneticist to Calico's roster. Report
And Finally... Some generic drugs have had eye-popping price spikes. Report